The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Open accessAbstract
In patients with dermatomyositis (DM) the earliest lesion is microvasculopathy mediated by deposition of C5b-C9 membranolytic attack complex (MAC) on intramuscular capillaries. This leads sequentially to muscle ischemia, necrosis of muscle fibers, and muscle weakness. High-dose intravenous immunoglobulin (IVIG), which can modulate complement-dependent tissue damage in animal models, has been shown to be effective in the treatment of patients with DM. We used an in vitro C3 uptake assay to examine 55 coded sera from 13 patients with DM and 5 patients with other non-complement-mediated neuromuscular diseases, before and after treatment with IVIG or placebo. Patients with active DM had a significantly higher baseline C3 uptake compared with the others (geometric mean 12,190 vs 3,090 cpm). Post-IVIG but not post-placebo sera inhibited the C3 uptake, without depleting the complement components, by 70.6-93.4%. The maximum inhibition of C3 uptake occurred within hours after IVIG infusion, started to rebound 2 d later, and reached pretreatment levels after 30 d. The serum levels of SC5b-9 complex production were high at baseline but normalized after IVIG therapy. Repeat biopsies from muscles of improved patients showed disappearance of C3b NEO and MAC deposits from the endomysial capillaries and restoration of the capillary network. We conclude that IVIG exerts its beneficial clinical effect by intercepting the assembly and deposition of MAC on the endomysial capillaries through the formation of complexes between the infused immunoglobulins and C3b, thereby preventing the incorporation of activated C3 molecules into C5 convertase. These findings provide the first serological and in situ evidence that IVIG modulates complement attack in a human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Imbach, P., d'APUZZO, V., Hirt, A., Rossi, E., Vest, M., Barandun, S., Baumgartner, C., Morell, A., Schöni, M., & Wagner, H. P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92400-4 · Cited by 1,666
The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin
Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P., Mason, W. H., Reddy, V., Sanders, S. P., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608073150601 · Cited by 1,419
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Self-citationPolymyositis, Dermatomyositis, and Inclusion-Body Myositis
Dalakas, M. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252107 · Cited by 938
Self-citationThe isolation of IgG from mammalian sera with the aid of caprylic acid
Steinbuch, M., & Audran, R. (1969) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(69)90285-9 · Cited by 860
Polymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J. L., Wedderburn, L. R., & Hanna, M. G. (2013) · Wiley eBooks · doi:10.1002/9781118635469.ch33 · Cited by 824
Polymyositis, Dermatomyositis, and Inclusion Body Myositis
Holton, J., Wedderburn, L. R., & Hanna, M. G. (2013) · UCL Discovery (University College London) · Cited by 764
Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis
Kissel, J. T., Mendell, J. R., & Rammohan, K. W. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602063140601 · Cited by 524
Microvascular changes in early and advanced dermatomyositis: A quantitative study
Emslie‐Smith, A. M., & Engel, A. G. (1990) · Annals of Neurology · doi:10.1002/ana.410270402 · Cited by 426
Leung, D. M., Kurt-Jones, E., Newburger, J., Cotran, R., Burns, J., & Pober, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91910-7 · Cited by 381
Illa, I., Leon‐Monzon, M., & Dalakas, M. C. (1992) · Annals of Neurology · doi:10.1002/ana.410310109 · Cited by 178
Self-citationKoski, C. L., Sanders, M. E., Swoveland, P. T., Lawley, T. J., Shin, M. L., Frank, M. M., & Joiner, K. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113231 · Cited by 149
Clinical, Immunopathologic, and Therapeutic Considerations of Inflammatory Myopathies
Dalakas, M. C. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199210000-00001 · Cited by 72
Self-citationInflammatory and toxic myopathies.
Dalakas, M. C. (1992) · PubMed · Cited by 27
Self-citation
Cited by
Polymyositis and dermatomyositis
Dalakas, M. C., & Hohlfeld, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14368-1 · Cited by 1,416
Self-citationImmunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Inclusion body myositis and myopathies
Griggs, R. C., Askanas, V., DiMauro, S., Engel, A., Karpati, G., Mendell, J. R., & Rowland, L. P. (1995) · Annals of Neurology · doi:10.1002/ana.410380504 · Cited by 837
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update
Appel, G. B., Cook, H. T., Hageman, G., Jennette, J. C., Kashgarian, M., Kirschfink, M., Lambris, J. D., Lanning, L., Lutz, H. U., Meri, S., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010078 · Cited by 380
Metadata
- Authors
- Basta, M., & Dalakas, M. C.
- Venue
- Journal of Clinical Investigation
- Published
- 1994-11-01
- Volume
- 94
- Issue
- 5
- Pages
- 1729-1735
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2013362643
- Cited by
- 396
- References
- 16
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.